COVID-19 Vaccine Response in People with Multiple Sclerosis.

"Potential Conflicts of Interest Biogen, Merck, Novartis, Roche, Sanofi/Genzyme, and Teva all manufacture multiple sclerosis disease modifying therapies that were used in this study, or which could be affected by the study. The following authors have received speaker fees, consultancy fees, and/ or travel expenses to attend educational meetings from one or more of these companies: E.C.T., D.B., R.D., N.E., G.G., A.K., N.P.R., K.S., S.J., M.J.S., and A.G. are co‐founders of and holds equity in ImmunoServ Ltd., which provided T‐cell analysis. N.V., V.A., A.N.A., J.B., K.B., R.C., K.G., L.G., A.G., K.E.H., A.H., G.I., M.J., A.S.K., S.L., S.J.M., S.N.S., J.S., M.U., and M.W. have no conflicts of interest to declare."

"The authors would like to acknowledge the help of Swee Vickie Nixon, Ray Wynford‐Thomas, Marija Cauchi, Catherine McConnell, Cynthia Butcher, Miranda Maria Piana Parra, Joseph Bishop, and Raees Samli in the running of the study. UHW: Support for equipment and consumables was provided by Cardiff and Vale UHB and Cardiff University. Kantaro Biosciences, LLC, kindly provided quantitative COVID‐19 serologic test kits to measure antibody levels for participants in this study. Salary for Samantha Loveless was partly provided by the BRAIN Unit Infrastructure Award (Grant no: UA05). The BRAIN Unit is funded by Welsh Government through Health and Care Research Wales. QMUL: Work performed as part of this study at QMUL is funded by Merck Serono Ltd., Feltham, UK, an affiliate of Merck KGaA with additional support from the MS community via crowdfunding. Assay development was funded by Barts Charity. This work was performed within the PNU, which is funded by Barts Charity."